论文信息 - Randomized Phase II Study of Paclitaxel plus Alisertib versus Paclitaxel plus Placebo as Second-Line Therapy for SCLC: Primary and Correlative Biomarker Analyses - 字舞流文

Randomized Phase II Study of Paclitaxel plus Alisertib versus Paclitaxel plus Placebo as Second-Line Therapy for SCLC: Primary and Correlative Biomarker Analyses

K. Nackaerts | Siân Jones | A. Chiang | T. Owonikoko | L. Byers | H. Niu | C. Chouaid | G. Ostoros | C. Baik | M. Bryant | S. Badola | A. Chiappori | T. Csoszi | C. Belani | G. Speranza | J. Ecsedy | A. Joy | V. Kolek | J. Roubec | M. Majem | B. Bahamon | E. Sheldon-Waniga | K. Czebe | E. Santos | J. C. Jaime | M. Patel | Miguel Williams | Z. Márk | Cong Li | E. Kong | Hyunjin Shin | Lisa Bedford | M. Williams | T. Csőszi